Interferon beta-1b treatment modulates TNFα and IFNγ spontaneous gene expression in MS

Neurology

Volumn 52, Issue 9, 1999, Pages 1764-1770

  Gayo, A ^a   Mozo, L ^b   Suarez A ^b   Tunon A ^a   Lahoz, C ^b   Gutierrez G ^b  

^a Departments of Immunology   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERFERON BETA SERINE; MEPREDNISONE; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE;

EID: 0033015085     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.52.9.1764     Document Type: Article

References (35)

1. The IFNβ Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:655-661.
2. Paty DW, Li DKB, UBC MS/MRI Study Group and the IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: II. MRI analysis of results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology 1993;43:662-667.
3. The IFNβ Multiple Sclerosis Study Group and the University of British Columbia MS/MR Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology 1995;45:12771285.
4. Rudick RA, Ransohoff RM. Biological effects of interferons: relevance to multiple sclerosis. Mult Scier Clin Lab Res 1995; 1:S12-S16.
5. Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology 1997;49:1111-1116.
6. Chabot S, Williams G, Yong VW. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferon beta-1b. J Clin Invest 1997;1:604-612.
7. Panitch HS, Folus JS, Johnson KP. Beta interferon prevents HLA class antigen induction by gamma interferon in MS. Neurology 1989;39(suppl 1):171.
8. Barna BP, Chou SM, Jacobs B, Yen-Lieberman B, Ransohoff RM. Interferon beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes. J Neuroimmunol 1989;23:45-53.
9. Abu-khabar KS, Armstrong JA, Ho M. Type I interferon (IFNalpha and beta) suppress cytotoxin (tumor necrosis factor alpha and lymphotoxin) production by mitogen-stimulated human peripheral blood mononuclear cell. J Leukoc Biol 1992; 52:162-172.
10. Brod SA, Marshall GD, Henninger EM, Sriram S, Khan M, Wolinsky JS. Interferon β1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis. Neurology 1996;46:1633-1638.
11. Noronha A, Toscas A, Jensen MA. Interferon beta augments suppressor cell function in multiple sclerosis. Ann Neurol 1990;27:207-210.
12. Beck J, Rondot P, Catinot L, Falcoff F, Kirchner H, Wietzerbin J. Increased production of interferon-gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 1988;78:318-323.
13. Chofflon M, Juillard C, Juillard P, Gauthier G, Grau GE. Tumor necrosis factor-alpha production as a possible predictor of relapse in patients with multiple sclerosis. Eur Cytokine Netw 1992;3:523-531.
14. Sharief MK, Hentges R. Association between TNF-α and disease progression in patients with multiple sclerosis. N Engl J Med 1991;325:467-472.
15. Panitch HS, Hirsch RL, Schinder J, Johnson KP. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology 1987;37:1097-1102.
16. Kennedy MK, Torrance DS, Picha KS, Mohler KM. Analysis of cytokine mRNA expression in the central nervous system of mice with experimental allergic encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J Immunol 1992;149:2469-2505.
17. Navikas V, Link J, Palasik W, et al. Increased mRNA expression of IL-10 in mononuclear cells in multiple sclerosis and optic neuritis. Scand J Immunol 1995;41:171-178.
18. Coclet-Ninin J, Dayer JM, Burger D. Interferon beta not only inhibits interleukin-1 beta and tumor necrosis factor-alpha but stimulates interleukin receptor antagonist production in human peripheral blood mononuclear cells. Eur Cytokine Netw 1997;8:345-349.
19. Noronha A, Toscas A, Jensen MA. Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis. J Neuroimmunol 1993;46:145-153.
20. Petereit HF, Bamborschke S, Esse AD, Heiss WD. Interferongamma-producing blood lymphocytes are decreased by interferon beta therapy in patients with multiple sclerosis. Mult Scler 1997;3:180-183.
21. Dayal AS, Jensen MA, Lledo A, Arnason BGW. Interferongamma secreting cells in multiple sclerosis patients treated with interferon-beta 1b. Neurology 1995;45:2173-2177.
22. Revel M, Chebath J, Mangelus M, Harroch S, Moviglia GA. Antagonism of interferon beta on interferon gamma: inhibition of signal transduction in vitro and reduction of serum levels in multiple sclerosis patients. Mult Scler 1995;(suppl 1):S5-S11.
23. Pette M, Pette DF, Muraro PA, Farnon E, Martin R, McFarland HF. Interferon-b interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 1997;49:385-392.
24. Poser CM, Paty DW, Sheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
25. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
26. Gayo A, Mozo L, Suarez A, Tunon A, Lahoz C, Gutierrez C. Glucocorticoids increase IL-10 expression in multiple sclerosis patients with acute relapse. J Neuroimmunol 1998;85:122130.
27. Guillaland G, Perrin S, Blanchard K, Bunn HF. Analysis of cytokine mRNA and DNA. Detection and quantitation by competitive polymerase. Proc Natl Acad Sci USA 1990;87:27252729.
28. Raeymaekers L. Quantitative PCR. Theoretical considerations with practical implications. Ann Biochem 1993;214:582-585.
29. Wucherpfnning KW. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition. Clin Immunol Immunopathol 1994;72:293-306.
30. Vassalli P. The pathophysiology of tumor necrosis factor. Ann Rev Immunol 1992;10:411-452.
31. Trincheri G, Perussia B. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 1985;6: 131-136.
32. Rudick RA, Ransohoff RM, Peppier R, VanderBrug Menderdorp S, Lehmann P, Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-627.
33. Porrini AM, Gambi D, Reder AT. Interferon beta effects on interleukin-10 secretion: mononuclear cell response to interleukin 10 is normal in multiple sclerosis patients. J Neuroimmunol 1995;61:27-34.
34. Rep MHG, Hintzen RQ, Polman CH, van Lier RAW. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996;67:111-118.
35. Noronha A, Jensen M, Toscas A. TGF-β activity in MS: effect of IFN-β. Neurology 1993;43(suppl):A355. Abstract.